Susan Galbraith, EVP Oncology R&D

Lorem ipsum dolor sit amet

JPG 669KB

Susan Galbraith is the Executive Vice President of Oncology R&D at AstraZeneca, with global accountability for the Oncology portfolio from discovery through to late-stage development. Susan is transforming the productivity and scientific output from Oncology R&D, leading the charge for exploring the next wave of cancer treatment regimens, including therapies that directly target cancer cells, others that harness the power of the immune system, and novel combinations that may result in deeper, more durable responses. To date, Susan has been instrumental in bringing 12 cancer medicines to patients. 

A Clinical Oncologist by background, Susan trained in medicine at Manchester and Cambridge Universities and has a PhD from the University of London. In recognition of her contributions to Oncology drug development, she was awarded an honorary Doctorate of Medical Science from the Institute of Cancer Research (ICR) in 2017, admitted to Fellowship of the Academy of Medical Sciences in 2018 and elected to the Academy of the American Association for Cancer Research (AACR) in 2024.

Susan is well known in the scientific community for her thought leadership and collaboration with clinicians, academic physicians, governments and the broader pharmaceutical industry. In addition to her role with AstraZeneca, Susan is a member of the Cambridge Cancer Centre Executive Committee and the Scientific Advisory Board of the ICR. From 2021-2024 she served on the Board of Directors of the AACR and currently serves on the European Association of Cancer Research (EACR) Advisory Council.

Discover how Susan Galbraith is driving innovation in cancer research

By attacking cancer from multiple angles, treating earlier and smarter, and harnessing transformational technologies, we are transforming outcomes and moving towards our ambition of one day eliminating cancer as a cause of death.

Susan Galbraith Executive Vice President, Oncology R&D, AstraZeneca

Publications

From drug development in cancer medicines to diversity in clinical trials, discover the topics Susan has recently contributed to in leading scientific journals.

Cabrera C, Fernández-Llaneza D, Ghazoui Z, D'Abrantes S, Esparza-Franco MA, Sopp C, Maj B, Chiou VL, Valastro B, Pangalos MN, Galbraith S, Ghiorghiu S, Massacesi C. Diversity of US participants in AstraZeneca-sponsored clinical trials. Contemp Clin Trials. 2024 Mar 11. doi: 10.1016/j.cct.2024.107496.

Durán CO, Bonam M, Björk E, Hughes R, Ghiorghiu S, Massacesi C, Campbell A, Hutchison E, Pangalos MN, Galbraith S. Implementation of digital health technology in clinical trials: the 6R framework. Nat Med. 2023 Nov;29(11):2693-2697. doi: 10.1038/s41591-023-02489-z. PMID: 37587220.

Reynolds AR, Moschetta M, Yohannes AR, Walcott F, Ashford M, Szucs Z, Sarbajna T, Hadfield J, Harrison E, Challis BG, Hernandez AG, Schiavon G, Germa C, Zorenyi G, Crean B, Galbraith S. A View on Drug Development for Cancer Prevention. Cancer Discov. 2023 May 4;13(5):1058-1083. doi: 10.1158/2159-8290.CD-22-0776. PMID: 37067191.

Lazar V, Girard N, Raymond E, Martini JF, Galbraith S, Raynaud J, Bresson C, Solomon B, Magidi S, Nechushtan H, Onn A, Berger R, Chen H, Al-Omari A, Ikeda S, Lassen U, Sekacheva M, Felip E, Tabernero J, Batist G, Spatz A, Pramesh CS, Girard P, Blay JY, Philip T, Berindan-Neagoe I, Porgador A, Rubin E, Kurzrock R, Schilsky RL. Transcriptomics in Tumor and Normal Lung Tissues Identify Patients With Early-Stage Non-Small-Cell Lung Cancer With High Risk of Postsurgery Recurrence Who May Benefit From Adjuvant Therapies. JCO Precis Oncol. 2022 Sep;6:e2200072. doi: 10.1200/PO.22.00072. PMID: 36108261; PMCID: PMC9489166.

Gill SJ, Wijnhoven PWG, Fok JHL, Lloyd RL, Cairns J, Armenia J, Nikkilä J, Lau A, Bakkenist CJ, Galbraith S, Vens C, O'Connor MJ. Radiopotentiation Profiling of Multiple Inhibitors of the DNA Damage Response for Early Clinical Development. Mol Cancer Ther. 2021 Sep;20(9):1614-1626. doi: 10.1158/1535-7163.MCT-20-0502. Epub 2021 Jun 22. PMID: 34158341; PMCID: PMC8650722.